Preventing vasospasm improves outcome after aneurysmal subarachnoid hemorrhage: rationale and design of CONSCIOUS-2 and CONSCIOUS-3 trials.
Cerebral vasospasm after aneurysmal subarachnoid hemorrhage (aSAH) is a frequent but unpredictable complication associated with poor outcome. Current vasospasm therapies are suboptimal; new therapies are needed. Clazosentan, an endothelin receptor antagonist, has shown promise in phase 2 studies, and two randomized, double-blind, placebo-controlled phase 3 trials (CONSCIOUS-2 and CONSCIOUS-3) are underway to further investigate its impact on vasospasm-related outcome after aSAH. Here, we describe the design of these studies, which was challenging with respect to defining endpoints and standardizing endpoint interpretation and patient care. Main inclusion criteria are: age 18-75 years; SAH due to ruptured saccular aneurysm secured by surgical clipping (CONSCIOUS-2) or endovascular coiling (CONSCIOUS-3); substantial subarachnoid clot; and World Federation of Neurosurgical Societies grades I-IV prior to aneurysm-securing procedure. In CONSCIOUS-2, patients are randomized 2:1 to clazosentan (5 mg/h) or placebo. In CONSCIOUS-3, patients are randomized 1:1:1 to clazosentan 5, 15 mg/h, or placebo. Treatment is initiated within 56 h of aSAH and continued until 14 days after aSAH. Primary endpoint is a composite of mortality and vasospasm-related morbidity within 6 weeks of aSAH (all-cause mortality, vasospasm-related new cerebral infarction, vasospasm-related delayed ischemic neurological deficit, neurological signs or symptoms in the presence of angiographic vasospasm leading to rescue therapy initiation). Main secondary endpoint is extended Glasgow Outcome Scale at week 12. A critical events committee assesses all data centrally to ensure consistency in interpretation, and patient management guidelines are used to standardize care. Results are expected at the end of 2010 and 2011 for CONSCIOUS-2 and CONSCIOUS-3, respectively.
Macdonald
R Loch
RL
Division of Neurosurgery, St. Michael's Hospital, University of Toronto, 30 Bond Street, Toronto, Ontario, M5B 1W8, Canada. macdonaldlo@smh.ca
Higashida
Randall T
RT
Keller
Emanuela
E
Mayer
Stephan A
SA
Molyneux
Andy
A
Raabe
Andreas
A
Vajkoczy
Peter
P
Wanke
Isabel
I
Frey
Aline
A
Marr
Angelina
A
Roux
Sébastien
S
Kassell
Neal F
NF
D003131:Combined Modality Therapy; D004146:Dioxanes / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D065130:Endothelin A Receptor Antagonists; D006801:Humans; D010919:Placebos; D011183:Postoperative Complications / Q000517:prevention & control; D017410:Practice Guidelines as Topic; D011725:Pyridines / Q000008:administration & dosage*; D011743:Pyrimidines / Q000008:administration & dosage*; D016032:Randomized Controlled Trials as Topic / Q000379:methods*; D013345:Subarachnoid Hemorrhage / Q000150:complications / Q000188:drug therapy / Q000601:surgery; D013449:Sulfonamides / Q000008:administration & dosage*; D013777:Tetrazoles / Q000008:administration & dosage*; D020301:Vasospasm, Intracranial / Q000209:etiology* / Q000517:prevention & control*
D004146:Dioxanes; D065130:Endothelin A Receptor Antagonists; D010919:Placebos; D011725:Pyridines; D011743:Pyrimidines; D013449:Sulfonamides; D013777:Tetrazoles; C109641:clazosentan